Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 30 Results

Title
Intervention Indication Therapeutic Area Year Actions
Leuprorelin acetate in addition to tamoxifen or an aromatase inhibitor for ER-positive early stage breast cancer in premenopausal women - adjuvant Leuprorelin acetate (Prostap DCS; Prostap Depot) , Tamoxifen Breast cancer Breast Cancer 2018 View  |  Download
Olaparib for BRCA mutated and high risk HER2 negative breast cancer - adjuvant therapy Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Breast cancer Breast Cancer 2020 View  |  Download
Palbociclib for breast cancer - post neoadjuvant therapy Palbociclib (Ibrance; PD-0332991) Breast cancer Breast Cancer 2020 View  |  Download
Pembrolizumab (Keytruda) for triple negative breast cancer Pembrolizumab (Keytruda; MK-3475) Breast cancer Breast Cancer 2017 View  |  Download
Pembrolizumab in addition to Chemotherapy for Locally Advanced, Non-Metastatic Triple Negative Breast Cancer – neoadjuvant, first line Pembrolizumab (Keytruda; MK-3475) Breast cancer Breast Cancer 2018 View  |  Download
Pembrolizumab in addition to chemotherapy for locally recurrent, inoperable or metastatic triple-negative breast cancer - first line Pembrolizumab (Keytruda; MK-3475) Breast cancer Breast Cancer 2018 View  |  Download
Pembrolizumab in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for early-strage breast cancer Pembrolizumab (Keytruda; MK-3475) Breast cancer Breast Cancer 2021 View  |  Download
Pertuzumab and trastuzumab (fixed-dose combination) in addition to chemotherapy for breast cancer Pertuzumab and Trastuzumab (Phesgo; RO7198574) (fixed dose combination: Trastuzumab; Pertuzumab) Breast cancer Breast Cancer 2019 View  |  Download
Ribociclib (Kisqali) and fulvestrant for advanced HR positive, HER2‐negative breast cancer in postmenopausal women, first or second line Fulvestrant (Faslodex) , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer Breast Cancer 2017 View  |  Download
Ribociclib and Fulvestrant and PI3K Inhibitor (Buparlisib or Alpelisib) for HR Positive, HER2 Negative Postmenopausal Breast Cancer – Second or Third Line Alpelisib (BYL719; Piqray) , Fulvestrant (Faslodex) , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer Breast Cancer 2017 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications